MyFibroScan
Free
2.4.0for iPhone, iPad and more
Age Rating
MyFibroScan Screenshots
About MyFibroScan
FibroScan® is the non-invasive solution for comprehensive management of liver health.
Fibroscan® provides unique and patented biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 2500 peer-reviewed publications and 60+ international guidelines.
myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way :
The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting Fibroscan® examination results.
Scores enhance Fibroscan® liver disease assessment with biological markers.
Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.
- Agile™3+ is an aid to identify NAFLD patients with advanced fibrosis by combining VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins.
- Agile™4 is an aid to early identify NAFLD patients with cirrhosis by combining VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin.
- Fast™ is an aid to identify at risk NASH patients defined as NASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (NAFLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast™.
Fibroscan® provides unique and patented biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 2500 peer-reviewed publications and 60+ international guidelines.
myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way :
The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting Fibroscan® examination results.
Scores enhance Fibroscan® liver disease assessment with biological markers.
Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.
- Agile™3+ is an aid to identify NAFLD patients with advanced fibrosis by combining VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins.
- Agile™4 is an aid to early identify NAFLD patients with cirrhosis by combining VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin.
- Fast™ is an aid to identify at risk NASH patients defined as NASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (NAFLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast™.
Show More
What's New in the Latest Version 2.4.0
Last updated on Apr 19, 2024
Old Versions
Technological update with new development framework
Show More
Version History
2.4.0
Apr 19, 2024
Technological update with new development framework
2.3.0
May 19, 2022
myFibroScan is now available in Spanish
2.2.2
Nov 23, 2021
Fix an issue to enter decimal value
2.2.1
Jun 17, 2021
Introduction of novel FibroScan based scores: Agile™ 3+ and Agile™ 4 for the identification of advanced fibrosis and cirrhosis in patients suspected of NAFLD.
2.1.1
Sep 24, 2020
Compliancy with latest Pubmed constraints and iOS 13 requirements
2.1.0
Feb 6, 2020
Introduction of FAST™ score, highly scalable score for at-risk NASH patients identification combining FibroScan® biomarkers of liver fibrosis (VCTE™) and steatosis (CAP™) with blood biomarker of liver inflammation (AST)
2.0.1
Nov 7, 2019
Introduction of FAST™ score, highly scalable score for at-risk NASH patients identification combining FibroScan® biomarkers of liver fibrosis (VCTE™) and steatosis (CAP™) with blood biomarker of liver inflammation (AST).
1.3.9
Apr 3, 2018
New feature EASL 2018 - Interpretation Guides: According to scientific publications, assist all FibroScan users in interpreting patient examinations results (Fibrosis stage and Steatosis grade)
1.2.1
Apr 19, 2017
Minor bug corrections
1.2.0
Apr 16, 2017
MyFibroScan FAQ
MyFibroScan is available in regions other than the following restricted countries:
China
MyFibroScan supports English
Click here to learn how to download MyFibroScan in restricted country or region.
Check the following list to see the minimum requirements of MyFibroScan.
iPhone
Requires iOS 13.0 or later.
iPad
Requires iPadOS 13.0 or later.
iPod touch
Requires iOS 13.0 or later.